SPARC Sun Pharma Advanced Research Company Q2 FY26 results (Jul–Sep 2025) and concall
SPARC's R&D Day conference call outlined a strategic pivot towards oncology and immunology, driven by past clinical trial setbacks. The company has prioritized two key clinical programs, SCD-153 and SBO-154, with clear milestones for 2026 and 2027. Significant cost optimization efforts have yielded $10 million in annual fixed cost savings and a projected reduction in operational spend. However, the company acknowledges the need for substantial additional funding to support its early-stage portfolio and extend its cash runway to FY28.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 38.5%, net profit up 29.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 13 | 15 | 27 | 10 | 8 −38% |
| EBITDA | -103 | -74 | -53 | -52 | -66 +36% |
| Net profit | -107 | -80 | -60 | -52 | -76 +29% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
